The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EMA extends the license indications for rituximab and venetoclax

Feb 12, 2020
Share:

The therapeutic potential of two lymphoma therapies has been broadened following the January 2019 European Medicines Agency (EMA) meeting. The EMA has announced license extensions of rituximab and the combination of venetoclax with obinutuzumab.1

The anti-CD20 monoclonal antibody, rituximab, has now been licensed for the treatment of children (≥ six months old) with advanced diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.1

The EMA has also extended the use of venetoclax in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).1 The combination was approved for this indication by the U.S. Food and Drug Administration (FDA) on May 15, 20192 — read more on the Lymphoma Hub here. The National Institute for Health and Care Excellence (NICE) is currently deciding if the treatment regimen should become available on the NHS.

  1. Lymphoma-action. More treatment options for DLBCL, Burkitt lymphoma and CLL.https://lymphoma-action.org.uk/more-treatment-options-dlbcl-burkitt-lymphoma-and-cll. Published February 11, 2020 [Accessed February 11, 2020]
  2. FDA. FDA approves venetoclax for CLL and SLL. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-and-sll. Published May 15, 2019 [Accessed February 11, 2020]

Share: